Publications & Presentations in the therapeutic area :

A population PK analysis of docetaxel after IV administration of CPC634 (CriPec® docetaxel) and generic docetaxel in plasma and tumor.

Zeiser S., Rietveld P., Rijcken C., Snelder N. A population PK analysis of docetaxel after IV administration of CPC634 (CriPec® docetaxel) and generic docetaxel in plasma and tumor. PAGE 2024 [Link to publication]

The effect of pH on intratumoural docetaxel release from polymeric nanoparticle CPC634.

Rietveld P,  Koolen S L.W. , Zeiser S., Snelder N., Rijcken C.J. , Koch B.C.P., Mathijssen R.H.J. , Sassen S.D.T. The effect of pH on intratumoural docetaxel release from polymeric nanoparticle CPC634. PAGE 2024 [Link to publication]

Case study of Exposure-Safety analysis in Phase 1 oncology – lessons learned.

Keunecke A., Goulooze S.C, Post T.M., Melhem M., Struemper H., Wang T. Case study of Exposure-Safety analysis in Phase 1 oncology – lessons learned. PAGE 2024 [Link to publication]

Development of a joint tumor size (TS)−overall survival (OS) modeling and simulation (M&S) framework supporting oncology development decision making.

Struemper H., Rathi C., Muliaditan M., Goulooze S.C., Mantero A., Post T.M., Visser S.A.G. Development of a joint tumor size (TS)−overall survival (OS) modeling and simulation (M&S) framework supporting oncology development decision making. PAGE 2023 [Link to publication]

Conditional Overall Survival (OS) Simulations With a Joint Tumor Size (TS)-OS Model to Support Oncology Development Decision Making.

Goulooze S.C., Muliaditan M., Mantero A., Visser S.A.G., Post T.M., Rathi C., Struemper H. Conditional Overall Survival (OS) Simulations With a Joint Tumor Size (TS)-OS Model to Support Oncology Development Decision Making. PAGE 2023. [Link to publication]

Longitudinal Efficacy and Safety Modeling and Simulation Framework to Aid Dose Selection of Belantamab Mafodotin for Patients with Multiple Myelo.

Collins J., Noort van M., Rathi C., Post T.M., Struemper H., Jewell  R.C., FerronBrady G. Longitudinal Efficacy and Safety Modeling and Simulation Framework to Aid Dose Selection of Belantamab Mafodotin for Patients with Multiple Myelo. CPT Pharmacometrics Syst. Pharmacol. 2023 [Link to publication].

A population K-PD model analysis of long-term testosterone inhibition in prostate cancer patients undergoing intermittent androgen deprivation therapy

DeJongh J., Ahsman M., Snelder N. A population K-PD model analysis of long-term testosterone inhibition in prostate cancer patients undergoing intermittent androgen deprivation therapy. J. Pharmacokinet. Pharmacodyn. 7 2021 [Link to publication].

Pharmacokinetic and pharmacodynamic modeling of the metastin/kisspeptin analog, TAK-448, for its anti-tumor efficacy in a rat xenograft model

Kogame A., Ishikawa K., DeJongh J., Tagawa Y., Matsui H., Moriya Y., Kondo T., Asahi S. Pharmacokinetic and pharmacodynamic modeling of the metastin/kisspeptin analog, TAK-448, for its anti-tumor efficacy in a rat xenograft model. Biopharm. Drug Dispos.: 2020.  [Link to publication]

Population pharmacokinetics of regorafenib in solid tumours

Keunecke A., Hoefman S., Drenth H.J., Zisowsky J., Cleton A., Ploeger B.A. Population pharmacokinetics of regorafenib in solid tumours: Exposure in clinical practice considering enterohepatic circulation and food intake. Br. J. Clin. Pharmacol.(December 2019): 1–15, 2020 [Link to publication]

Exploration of efficacious alternative regorafenib regimens to manage hand − foot skin reaction

Grothey A., Hoefman S., Ruppert M., Vis P., Zisowsky J., Cutsem E., Dochy E.v. Fiala-buskies S., Cleton A., Ploeger B. Exploration of efficacious alternative regorafenib regimens to manage hand − foot skin reaction. ESMO, 2019.

Expertise